Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
3211936
Reference Type
Journal Article
Title
Diabetic Macular Edema Diagnosis and Treatment in the Real World: An Analysis of Medicare Claims Data (2008 to 2010)
Author(s)
Dugel, PU; Layton, A; Varma, RB
Year
2016
Volume
47
Issue
3
Page Numbers
258-267
Language
English
PMID
26985800
DOI
10.3928/23258160-20160229-09
Abstract
BACKGROUND AND OBJECTIVE:
To characterize vascular endothelial growth factor (VEGF) inhibitor treatment patterns in patients with diabetic macular edema (DME) using a Medicare Standard Analytic Files Part B or Outpatient Claims database to understand treatment frequency and DME persistence.
PATIENTS AND METHODS:
A retrospective analysis of treatment patterns for patients diagnosed with DME receiving their first anti-VEGF injection was performed.
RESULTS:
The average number of anti-VEGF injection claims for DME per patient rose from 3.1 to 4.6 per year (mean: 4.2). Within 1 year of diagnosis, 46% of patients received their final DME diagnosis (mean: 1.9 anti-VEGF claims), and 65% of patients received their final anti-VEGF treatment for DME. Patients who received treatment for DME through years 2 and 3 submitted a mean of four and 7.2 anti-VEGF claims, respectively.
CONCLUSION:
VEGF inhibitor treatment was less frequent than in landmark trials, but did resolve DME in a proportion of patients. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:258-267.].
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity